Class / Patent application number | Description | Number of patent applications / Date published |
424269100 | Parasitic protozoan (e.g., Trypanosoma, Trichomonas, Leishmania, Entamoeba, etc.) | 88 |
20080206285 | COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF LEISHMANIASIS - Taught herein are therapeutic pharmaceutical compositions (vaccines) and methods for preventing or treating leishmaniasis and infections mediated by intracellular pathogenic micro-organism in mammals and in particular in humans, members of the dog, cat and horse family. The pharmaceutical compositions comprise composition of matter produced by from | 08-28-2008 |
20080241193 | CANINE LEISHMANIA VACCINE - The present invention provides vectors that contain and express in vivo | 10-02-2008 |
20090191242 | NOVEL HOMEOPATHIC STRAIN COMPRISING A NOSODE FROM A PROTOZOON OF THE GENUS TRYPANOSOMA - The present invention relates to a novel homeopathic strain characterized in that it comprises a nosode from a protozoon of the genus | 07-30-2009 |
20090208536 | Composition comprising fractions or sub-fraction of leishmania promastigotes or leishmania amastigotes called fucose mannose ligand (fml) and saponin, composition for preparation of leishmaniasis transmission blocking vaccines in humans and animals comprising fractions or sub-fractions of leishmania promastigotes or leis - The invention relates to a composition comprising | 08-20-2009 |
20090214595 | Means for Obtaining Avirulent Leishmania Promastigotes, Promastigotes Obtained, and the Applications Thereof - The invention relates to an expression vector of a gene coding for an antigenic protein of | 08-27-2009 |
20090324649 | LEISHMANIA VACCINE USING SAND FLY SALIVARY IMMUNOGEN - The present invention provides vectors that contain and express in vivo or in vitro sand fly | 12-31-2009 |
20100278869 | Plant Produced Vaccine for Amebiasis - Disclosed herein are methods of making a vaccine against | 11-04-2010 |
20100297186 | MULTICOMPONENT OR MONOCOMPONENT VACCINE TO BE USED AGAINST CHAGAS DISEASE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PROCEDURE FOR THE OBTENTION OF IMMUNOGEN OF SAID VACCINES, AND NUCLEIC ACID USED IN SAID PROCEDURE - A vaccine against the Chagas disease, capable of stimulating the immune response against the trans-sialidase virulence factor of the | 11-25-2010 |
20110008391 | VACCINE COMPOSITION AND IMMUNIZATION METHOD - The present invention refers to the recombinant vaccine against canine visceral leishmaniasis containing the recombinant A2 protein and saponin, as an adjuvant, allowing the distinction between vaccinated and infected animals through conventional ELISA or immunofluorescence tests that employ antigens of promastigote forms of | 01-13-2011 |
20110008392 | VACCINE TARGETS AND DELIVERY SYSTEMS FOR CRYPTOSPORIDIUM - Compositions comprising the | 01-13-2011 |
20110081383 | LIVE ATTENUATED LEISHMANIA VACCINES - Targeted disruption of the centrin gene leads to attenuation of growth in the | 04-07-2011 |
20110212135 | OLIGODEOXYNUCLEOTIDE AND ITS USE TO INDUCE AN IMMUNE RESPONSE - D type CpG oligodeoxynucleotides are provided herein that include a sequence represented by the following formula: | 09-01-2011 |
20120128722 | Novel Monensin Derivatives for the Treatment and Prevention of Protozoal Infections - This invention relates to novel polyether ionophores, formulations comprising same, and to methods of making and using these compounds and formulations for the treatment and/or prevention of parasitic infection in animals and humans. These compounds exhibit improved safety profiles and/or efficacies as compared to parent compounds. | 05-24-2012 |
20120141535 | PROCESS AND COMPOSITION FOR TREATMENT OF CANINE AND HUMAN LEISHMANIASIS - Process and immune chemotherapeutic/pharmaceutical composition for treatment of canine and human Leishmaniasis comprising a vaccine containing the FML antigen (Fucose Mannose-Ligand) and saponin adjuvant, used in association with chemotherapeutic agents, showing healing property, leaving the dogs previously infected, in the condition of sterile cure of visceral and tegumentary leishmaniasis, characterized by absence of parasites and the overall absence of | 06-07-2012 |
20120164179 | Leishmania Challenge Model - The present invention provides a method for effectively and reproducibly infecting canines with | 06-28-2012 |
20120244191 | COMPOSITIONS AND METHODS FOR CONTROLLING DISEASES IN ANIMALS - Disclosed herein are compositions for the treatment of a disease in an animal including yeast extract of | 09-27-2012 |
20120288524 | LEISHMANIA-BASED CARRIER FOR VACCINE DELIVERY - The present invention provides a composition for delivering a protein vaccination candidate to a mammalian subject having a | 11-15-2012 |
20130216578 | RECOMBINANT TRYPANOSOMA THEILERI PARASITE - The present invention relates to the field of the veterinary medicine of bovine animals. In particular the invention relates to a recombinant | 08-22-2013 |
20130224249 | RECOMBINANT TRYPANOSOMA CRUZI CELLS USEFUL AS ANTI-CANCER IMMUNE AGENTS - Recombinant, attenuated parasites are transformed or transfected with nucleic acid molecules which provoke an immunostimulatory and protective response in subjects. Preferably, the parasite is | 08-29-2013 |
20130337014 | Compositions and Methods for Controlling Diseases in Animals - Disclosed herein are compositions for the treatment of a disease in an animal including yeast extract of | 12-19-2013 |
20140030293 | NEW ADJUVANT - The invention relates to a new adjuvant and to its use in combination with an antigen. | 01-30-2014 |
20140127266 | PLANT PRODUCED VACCINE FOR AMEBIASIS - Disclosed herein are methods of making a vaccine against | 05-08-2014 |
20140178437 | USE OF A FOOD ADDITIVE BASED ON AT LEAST ONE PHYTONUTRIENT FOR STIMULATING VACCINE IMMUNITY AGAINST APICOMPLEXA IN ANIMALS - The invention relates to the use of a food additive comprising at least one phytonutrient in order to stimulate vaccine immunity against | 06-26-2014 |
20140255448 | VACCINE COMPOSITION AND IMMUNIZATION METHOD - The present invention refers to the recombinant vaccine against canine visceral leishmaniasis containing the recombinant A2 protein and saponin, monophosphoryl lipid A, or aluminum hydroxide plus CpG as an adjuvant, allowing the distinction between vaccinated and infected animals through conventional ELISA or immunofluorescence tests that employ antigens of promastigote forms of | 09-11-2014 |
20150290183 | ANTIPARASITIC EFFECT OF BIS[3,5-BIS(BENZYLIDENE)-4-OXO-1-PIPERIDINYL]AMIDE DERIVATIVES - Embodiments are directed to compositions and methods for treating parasitic infections. Compounds have been identified from a library of anti-cancer drugs that serve as suitable agents for targeting trypanosomatids. | 10-15-2015 |
20150315254 | LUTZOMYIA LONGIPALPIS POLYPEPTIDES AND METHODS OF USE - Substantially purified salivary | 11-05-2015 |
424270100 | Babesia | 4 |
20080317786 | Genetically Modified Babesia Parasites Expressing Protective Tick Antigens and Uses Thereof - The present invention relates to methods for stable transfection of | 12-25-2008 |
20100310606 | VACCINATION WITH KILLED BUT METABOLICALLY ACTIVE (KBMA) PROTOZOANS WITH TOLL-LIKE RECEPTOR AGONISTS - This invention provides compositions for inducing an immune response in a vertebrate host against a protozoan parasite. In certain embodiments the composition comprises a protozoan parasite comprising a psoralen-modified DNA, whereby said protozoan parasite is killed but metabolically active (KBMA); and optionally a Toll-like receptor agonist. | 12-09-2010 |
20120093871 | MODIFIED PROTOZOAN EXPRESSING AT LEAST TWO VARIABLE SURFACE PROTEINS (VSP), A VACCINE COMPRISING IT AND PROCEDURES, USES, AND METHODS THEREOF - Modified protozoa parasites comprising simultaneous expression on its surface of at least two ariable surface proteins (VSP). The modified protozoa may also simultaneously express the complete repertoire of variable surface proteins. Protozoa show reduced expression of Dicer, RNA-dependant RNA-plymerase (RdRP) enzymes or both, wherein the RdRP gene and/or the Dicer gene has been silenced. The protozoan may be any protozoan showing an antigenic variation mechanism. | 04-19-2012 |
20160158327 | GENETICALLY MODIFIED BABESIA PARASITES EXPRESSING PROTECTIVE TICK ANTIGENS AND USES THEREOF - The present invention relates to methods for stable transfection of | 06-09-2016 |
424271100 | Eimeria | 7 |
20100015182 | COCCIDIOSIS VACCINES - The present invention discloses a vaccine that provides protection from coccidiosis, and methods of making and using the vaccine alone, or in combination with other protective agents. | 01-21-2010 |
20100166803 | EIMERIA VACCINE FOR TURKEYS - The present invention discloses a vaccine that provides protection to turkeys from coccidiosis, and methods of making and using the vaccine alone, or in combinations with other protective agents. In addition, the present invention discloses PCR primer sets that are useful in identifying the species of | 07-01-2010 |
20110217333 | Soft gel delivery system for treating poultry - The present invention is directed to a method of treating poultry hatchlings in a hatchling tray. The method comprises of providing a soft gel form capable of being dispensed through a spray nozzle, providing a spray dispensing apparatus, the apparatus being capable of delivering a predetermined volume of the gel as a plurality of small beadlets through a plurality of nozzles, placing the hatchling tray containing the hatchlings beneath the nozzles of the dispensing apparatus, dispensing the predetermined volume of the soft gel containing the therapeutic agent as small beadlets into the hatchling tray and allowing the hatchlings to consume the beadlets. The present invention is also directed to a dispensing apparatus for dispensing a therapeutic agent in a soft gel into a hatchling tray of poultry hatchlings. | 09-08-2011 |
20120308604 | ADJUVANT FOR THE PREPARATION OF VACCINE COMPOSITIONS INTENDED FOR THE PREVENTION OF COCCIDIOSIS - A vaccine adjuvant which, based on the 100% mass thereof, includes between 10% and 95% of a mineral oil containing: between 0.05 mass-% and 10 mass-% hydrocarbon chains having less than 16 carbon atoms, and between 0.05 mass-% and 5 mass-% hydrocarbon chains having more than 28 carbon atoms. In addition, the adjuvant has a P/N ratio, corresponding to the ratio of the mass quantity of the paraffinic hydrocarbon chains to the mass quantity of the naphthenic hydrocarbon chains, of between 2.5 and 3, the adjuvant being intended for the production of a vaccine composition to prevent coccidiosis. | 12-06-2012 |
20130017220 | GEL VACCINE DELIVERY SYSTEM FOR TREATING POULTRY - Safe and effective gel-bead vaccines for treating domesticated birds for diseases caused by cyst-forming protozoa, especially for coccidiosis. | 01-17-2013 |
20140086956 | ADJUVANT FOR THE PREPARATION OF VACCINE COMPOSITIONS INTENDED FOR THE PREVENTION OF COCCIDIOSIS - A vaccine adjuvant which, based on the 100% mass thereof, includes between 10% and 95% of a mineral oil containing: between 0.05 mass-% and 10 mass-% hydrocarbon chains having less than 16 carbon atoms, and between 0.05 mass-% and 5 mass-% hydrocarbon chains having more than 28 carbon atoms. In addition, the adjuvant has a P/N ratio, corresponding to the ratio of the mass quantity of the paraffinic hydrocarbon chains to the mass quantity of the naphthenic hydrocarbon chains, of between 2.5 and 3, the adjuvant being intended for the production of a vaccine composition to prevent coccidiosis. | 03-27-2014 |
20160175369 | COMPOSITIONS AND METHODS FOR REDUCING INFECTION IN POULTRY | 06-23-2016 |
424272100 | Plasmodium | 44 |
20080213318 | Malaria MSP-1 C-terminal enhanced subunit vaccine - A vaccine or immunogenic composition is described that contains recombinantly produced, secreted, forms of malaria MSP-1 C-terminal subunit proteins from any of the | 09-04-2008 |
20080317787 | Anti-Malaria Vaccine - There is provided, inter alia, a method for the prophylaxis of productive malaria infection in travelers to endemic regions comprising the administration of suitable amounts of a formulation comprising a | 12-25-2008 |
20090041808 | Detection/Measurement Of Malaria Infection Disease Utilizing Natural Immunity By Hemozoin Induction, Screening Of Preventative Or Therapeutic Medicine For Malaria Infection Disease, And Regulation Of Natural Immunity Induction - The instant invention is to provide a method for detecting and measuring malaria infection utilizing the induction by hemozoin (HZ); a method for screening a vaccine for malaria infection and a preventative or therapeutic agent for malaria infection using the method for detecting and measuring; and a means for regulating the induction of innate immunity using the HZ, synthetic HZ, or derivatives thereof as an adjuvant or immunostimulant. Malaria infection is detected and measured of by detecting and measuring HZ-induced, TLR9-mediated, and MyD88-dependent innate immune activity. The detection and measurement of malaria infection can be used to diagnose malaria infection. The method for detecting and measuring is also used for screening a vaccine for malaria infection and a preventative or therapeutic agent for malaria infection. Further, HZ, synthetic HZ, or derivatives thereof are used as an adjuvant or immunostimulant to regulate HZ-induced innate immune induction. | 02-12-2009 |
20090053265 | Antigenic peptides and their use - This invention relates generally to the field of pathogen peptidic antigens and their use, for example, for the preparation of a vaccine against said pathogen. More specifically, the present invention relates to an antigenic peptide deriving from | 02-26-2009 |
20090098166 | Chimeric MSP-based malaria vaccine - The invention provides an immunogenic composition comprising MSP-8 linked to an antigen. Methods of using the composition to induce an immune response in an animal are also provided. | 04-16-2009 |
20090148477 | ADENOVIRAL VECTOR-BASED MALARIA VACCINES - The invention provides adenoviral vectors comprising an adenoviral genome comprising heterologous antigen-encoding nucleic acid sequences, such as | 06-11-2009 |
20100062028 | VACCINES FOR MALARIA - The present invention relates to a novel hybrid/fusion protein derived from the CS protein of | 03-11-2010 |
20100092520 | Recombinant Plasmodium Falciparum Merozoite Surface Proteins 4 and 5 and Their Use - Accordingly, the invention provides constructs in which the nucleic acids encoding | 04-15-2010 |
20100112010 | Use of conditional plasmodium strains lacking an essential gene in malaria vaccination - The present invention relates to a malaria vaccine for administration to a host, comprising an attenuated malarial parasite with a gene that has been rendered non-functional, wherein the gene, when present in naturally occurring form, encodes a protein necessary for continued in vivo survival and proliferation of the parasite and/or for infection of host red blood cells. The gene that has been rendered non-functional can be, e.g., a gene that encodes a nutrient transporter protein or a gene that encodes an enzyme involved in phospholipid biosynthesis. The invention also provides kits and methods that include such attenuated malarial parasites. | 05-06-2010 |
20100183678 | CONJUGATES OF PLASMODIUM FALCIPARUM SURFACE PROTEINS AS MALARIA VACCINES - Conjugates of ookinete surface protein Pfs25 are provided that are efficacious as vaccines against | 07-22-2010 |
20100183679 | PRIMERS FOR DETECTING PLASMODIUM - The present invention provides an easy and rapid method for detecting/identifying the presence or absence of specific | 07-22-2010 |
20100183680 | Purified Plasmodium and Vaccine Compositions - Disclosed are substantially purified | 07-22-2010 |
20100239614 | Isolation and Purification of P. Falciparum Merozoite Protein-142 Vaccine - In this application is the expression and purification of a recombinant | 09-23-2010 |
20100247576 | NUCLEOTIDE AND AMINO ACID SEQUENCES ENCODING AN EXPORTED PROTEIN 1 DERIVED FROM PLASMODIUM VIVAX AND USES THEREOF - The present invention is directed to novel polynucleotides and polypeptides directed to EXP1 of | 09-30-2010 |
20100278870 | ADENOVIRAL VECTOR-BASED MALARIA VACCINES - The invention provides a method of inducing an immune response against malaria in a mammal. The method comprises intramuscularly administering to a mammal a composition comprising a pharmaceutically acceptable carrier and either or both of (a) a first adenoviral vector comprising a nucleic acid sequence encoding a | 11-04-2010 |
20100297187 | PEPTIDE SEQUENCES AND COMPOSITIONS - Provided is a polypeptide composition comprising one or more polypeptides, which polypeptides are immunogenic in a vertebrate such that they cause the vertebrate to produce immune system cells capable of recognising at least one epitope from an arthropod saliva protein fraction, wherein the arthropod saliva protein fraction has a mass of 40 kDA or less, and wherein the polypeptides are selected independently from:
| 11-25-2010 |
20100330126 | Attenuated malaria blood-stage vaccine - The present invention relates to an attenuated | 12-30-2010 |
20110020405 | VACCINE COMPRISING A RIBOSOMAL PROTEIN EXTRACT (RPE) AND OPTIONALLY A TH1-PROMOTING ADJUVANT - The invention relates to composition comprising a RPE and optionally a Th | 01-27-2011 |
20110033502 | LIVE GENETICALLY ATTENUATED MALARIA VACCINE - Method for inoculating a vertebrate host against malaria, by administering to the host a live | 02-10-2011 |
20110171266 | MALARIA VACCINE - The present invention features immunogenic compositions based on pre-fertilization or post-fertilization antigens expressed in the circulating gametocytes in the peripheral blood of infected persons or on the malaria parastes' stages of develop-ment in the mosquito midgut including extracellular male and female gametes, fertilized zygote and ookinete. The invention also features methods to prevent the transmission of malaria using the immunogenic compositions of the invention. | 07-14-2011 |
20120014994 | Malaria prime/boost vaccines - Described are vaccine regimens in which specific prime/boost regimens are applied using low-neutralized recombinant adenoviral vectors harboring nucleic acids encoding antigens from | 01-19-2012 |
20120156245 | Methods for the Prevention of Malaria - This application relates to preventing malaria by administering a vaccine. More particularly, this invention relates to a vaccine against malaria infection compromising the administration of attenuated sporozoites to a human or animal. | 06-21-2012 |
20120269856 | STABLE IMMUNOGENIC PROTEIN HAVING MULTIPLE CYSTEINES MOLECULES PROCESS THEREFOR AND COMPOSITION THEREOF - The invention describes a stable immunogenic protein having multiple cysteines molecules wherein the protein is having stability up to two years and purity more than 98% particularly rPvRII and/or rPfF2. It also discloses a method for producing said immunogenic protein comprising the following steps: culturing the host | 10-25-2012 |
20120288525 | PHARMACEUTICAL COMPOSITIONS COMPRISING ATTENUATED PLASMODIUM SPOROZOITES AND GLYCOLIPID ADJUVANTS - Disclosed herein are pharmaceutical compositions comprising | 11-15-2012 |
20130017221 | PRIMERS FOR DETECTING PLASMODIUM - The present invention provides an easy and rapid method for detecting/identifying the presence or absence of specific | 01-17-2013 |
20130142829 | Mutant Parasites for Use as Vaccines and Platforms for Screening for Compounds - Cloning and characterization of a TgIF2α kinase from | 06-06-2013 |
20130171195 | LENTIVIRAL VECTOR BASED IMMUNOLOGICAL COMPOUNDS AGAINST MALARIA - The invention relates to lentiviral vector particles pseudotyped with a determined heterologous viral envelope protein or viral envelope proteins originating from a RNA virus and which comprise in its genome at least one recombinant polynucleotide encoding at least one polypeptide(s) carrying epitope(s) of an antigen of a | 07-04-2013 |
20130216579 | METHODS AND COMPOSTITIONS FOR GENE EDITING OF A PATHOGEN - Disclosed herein are methods and compositions for genome editing of the malarial parasite | 08-22-2013 |
20130216580 | HETEROLOGOUS PRIME BOOST VACCINATION REGIMEN AGAINST MALARIA - Described are methods for inducing an immune response in a subject against an antigen from a malaria-causing parasite, preferably | 08-22-2013 |
20130224250 | Purified Plasmodium and Vaccine Composition - Disclosed are substantially purified | 08-29-2013 |
20130251750 | Purified Plasmodium and Vaccine Composition - Disclosed are substantially purified | 09-26-2013 |
20130273112 | CONSENSUS ANTIGEN CONSTRUCTS AND VACCINES MADE THEREFROM, AND METHODS OF USING THE SAME TO TREAT MALARIA - Provided herein is consensus amino acid sequences of | 10-17-2013 |
20130295138 | ROADMAP FOR CONTROLLING MALARIA - Embodiments of the present invention concern methods of preventing malaria in a target population of humans comprising: uniformly administering a therapeutically effective amount of a live low dose malaria vaccine to each individual within the target population on each of two or three consecutive days. The methods include using | 11-07-2013 |
20140079736 | PLASMODIAL SURFACE ANION CHANNEL INHIBITORS FOR THE TREATMENT OR PREVENTION OF MALARIA - The invention provides methods of treating or preventing malaria comprising administering to an animal an effective amount of a compound of formula (I): Q-Y—R | 03-20-2014 |
20140093540 | IMMUNOGENIC COMPOSITIONS AND EXPRESSION SYSTEMS - Immunogenic compositions and vaccines against Plasmodial infection comprising an Rh polypeptide or a fragment or variant thereof are disclosed. Also disclosed are Rh5 polypeptides or fragments or variants thereof capable of binding CD147 and conferring protection against infection and/or disease caused by multiple Plasmodial strains or Plasmodial species, inhibitors of the interaction between Rh5 and CD147 and methods for producing polypeptides in a mammalian expression system. | 04-03-2014 |
20140120138 | PHARMACEUTICAL COMPOSITIONS COMPRISING ATTENUATED PLASMODIUM SPOROZOITES AND GLYCOLIPID ADJUVANTS - Disclosed herein are pharmaceutical compositions comprising | 05-01-2014 |
20140154289 | ATTENUATED PLASMODIUM WITH DEACTIVATED HMGB2 GENE, AS VACCINE - The present invention relates to novel compositions and methods for immunizing a host against malaria using a | 06-05-2014 |
20140186402 | Blood Stage Malaria Vaccine - An immunogenic composition for use as a blood-stage malaria vaccine, a method of producing the immunogenic composition and a method of treatment of malaria are provided. The immunogenic composition includes isolated or purified merozoites, or red blood cells infected with merozoites, treated with centanamycin or tafuramycin A. The immunogenic composition does not include an adjuvant. A single dose of the immunogenic composition is sufficient to protect an animal against subsequent malaria infection by the same isolate, strain or species of | 07-03-2014 |
20140335128 | ADENOVIRAL VECTOR-BASED MALARIA VACCINES - The invention provides a method of inducing an immune response against malaria in a mammal. The method comprises intramuscularly administering to a mammal a composition comprising a pharmaceutically acceptable carrier and either or both of (a) a first adenoviral vector comprising a nucleic acid sequence encoding a | 11-13-2014 |
20150071966 | RODENT PLASMODIUM PARASITES AS PLATFORMS FOR A WHOLE-ORGANISM MALARIA VACCINE - A method for inducing protective immunity in a vertebrate host against malaria, by administering to the host a live rodent | 03-12-2015 |
20150313981 | Purified Plasmodium and Vaccine Compositions - Disclosed are substantially purified | 11-05-2015 |
20150359869 | METHODS AND COMPOSITIONS FOR PREVENTING A CONDITION - Disclosed herein are nucleic acid-based vaccines against malaria and other conditions. A DNA construct comprising nucleic acid encoding one or more pathogen proteins, such as malaria parasite proteins, nucleic acid encoding a dendritic cell ligand, and a linker polynucleotide, is administered with an adjuvant and/or by electroporation to achieve in vivo results that are not achieved with the vaccine components alone. The vaccine can also be formulated using a fusion protein expressed by the disclosed nucleic acid, in combination with an adjuvant. | 12-17-2015 |
20160158351 | PHARMACEUTICAL COMPOSITIONS COMPRISING ATTENUATED PLASMODIUM SPOROZOITES AND GLYCOLIPID ADJUVANTS - Disclosed herein are pharmaceutical compositions comprising | 06-09-2016 |
20160175417 | Purified Plasmodium and Vaccine Compositions | 06-23-2016 |
424273100 | Toxoplasma | 7 |
20090053266 | Apicomplex vaccine strains of a family of sarcocystidae - The invention relates to attenuate mutated strains of apicomplex of a family of Sarcocystidae, containing inactivated MIC | 02-26-2009 |
20100203085 | Toxoplasma Gondii Vaccines and Uses Thereof - The present invention provides attenuated | 08-12-2010 |
20100260804 | Attenuated Uracil Auxotroph of an Apicomplexan and Use Thereof - Uracil auxotroph mutants of apicomplexans are provided which lack a functional carbamoyl phosphate synthase II (CPSII) enzyme. Also provided are | 10-14-2010 |
20120045477 | Method for Treating Cancer with Toxoplasma Gondii Vaccine - The present invention provides attenuated | 02-23-2012 |
20160017275 | USE OF ATTENUATED PARASITE STRAINS FOR THE PREVENTION AND/OR TREATMENT OF EYE WOUNDS ASSOCIATED WITH AN INFECTION BY TOXOPLASMA GONDII - Strains of | 01-21-2016 |
20160067321 | METHOD FOR TREATING PANCREATIC CANCER WITH TOXOPLASMA GONDII VACCINE - Attenuated | 03-10-2016 |
20160166662 | USE OF ATTENUATED STRAINS OF PARASITES FOR THE PREVENTION OR TREATMENT OF PATHOLOGIES ASSOCIATES WITH AN APICOMPLEXAN | 06-16-2016 |